Fundamental and clinical studies of cefixime granules in pediatrics

K. Sunakawa, N. Saito, Y. Ishizuka, S. Iwata, N. Kumagai, T. Yokota, T. Asaishi, S. Kusano, Y. Sato, Y. Kusumoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fundamental and clinical studies of cefixime (CFIX) granules, a new oral cephalosporin, were carried out with the following results: 1. The MICs of CFIX against 234 clinical isolates were determined. Antibacterial activities of the drug against S. aureus, S. epidermidis and E. faecalis were weaker than those of conventional oral cephalosporins but antibacterial activities against Gram-negative bacteria were almost the same as those of cehpem antibiotics of Fuji's group 5. 2. Peak serum concentrations of CFIX after oral doses of 3 and 6 mg/kg were, respectively, 1.51~4.89 μg/ml at 2~6 hours and 3.22~7.76 μg/ml at 4~8 hours. Serum concentrations of CFIX were dose-dependent in a patient given 3 and 6 mg/kg in a cross-over study. 3. CFIX granules were administered mainly to children suffering from respiratory tract infection, otitis media and urinary tract infection at a dose of 3 mg/kg b.i.d. or t.i.d. for 3~7 days. The clinical responses to CFIX were excellent to good in 44 of the 50 children with infections, with an effectiveness rate of 88%. 4. Thirty-five strains of the 40 clinical isolates were eradicated by the treatment with CFIX. The bacteriological eradication rate was 87.5%. 5. Side effects observed were diarrhea and soft stool in 2 patients each, and elevated GOT · GPT and eosinophilia in 1 patient each. These symptoms and laboratory abnormalities disappeared on the day after the completion of therapy with CFIX. From the above results it has been concluded that CFIX is a useful and safe antibiotic for treating various bacterial infections in children.

Original languageEnglish
Pages (from-to)1035-1054
Number of pages20
JournalJapanese Journal of Antibiotics
Volume39
Issue number4
Publication statusPublished - 1986
Externally publishedYes

Fingerprint

Cefixime
Pediatrics
Cephalosporins
Anti-Bacterial Agents
Clinical Studies
Otitis Media
Eosinophilia
Gram-Negative Bacteria
Serum
Bacterial Infections
Urinary Tract Infections
Respiratory Tract Infections
Cross-Over Studies
Diarrhea

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Sunakawa, K., Saito, N., Ishizuka, Y., Iwata, S., Kumagai, N., Yokota, T., ... Kusumoto, Y. (1986). Fundamental and clinical studies of cefixime granules in pediatrics. Japanese Journal of Antibiotics, 39(4), 1035-1054.

Fundamental and clinical studies of cefixime granules in pediatrics. / Sunakawa, K.; Saito, N.; Ishizuka, Y.; Iwata, S.; Kumagai, N.; Yokota, T.; Asaishi, T.; Kusano, S.; Sato, Y.; Kusumoto, Y.

In: Japanese Journal of Antibiotics, Vol. 39, No. 4, 1986, p. 1035-1054.

Research output: Contribution to journalArticle

Sunakawa, K, Saito, N, Ishizuka, Y, Iwata, S, Kumagai, N, Yokota, T, Asaishi, T, Kusano, S, Sato, Y & Kusumoto, Y 1986, 'Fundamental and clinical studies of cefixime granules in pediatrics', Japanese Journal of Antibiotics, vol. 39, no. 4, pp. 1035-1054.
Sunakawa K, Saito N, Ishizuka Y, Iwata S, Kumagai N, Yokota T et al. Fundamental and clinical studies of cefixime granules in pediatrics. Japanese Journal of Antibiotics. 1986;39(4):1035-1054.
Sunakawa, K. ; Saito, N. ; Ishizuka, Y. ; Iwata, S. ; Kumagai, N. ; Yokota, T. ; Asaishi, T. ; Kusano, S. ; Sato, Y. ; Kusumoto, Y. / Fundamental and clinical studies of cefixime granules in pediatrics. In: Japanese Journal of Antibiotics. 1986 ; Vol. 39, No. 4. pp. 1035-1054.
@article{d09817325b6347df897d5287173866ba,
title = "Fundamental and clinical studies of cefixime granules in pediatrics",
abstract = "Fundamental and clinical studies of cefixime (CFIX) granules, a new oral cephalosporin, were carried out with the following results: 1. The MICs of CFIX against 234 clinical isolates were determined. Antibacterial activities of the drug against S. aureus, S. epidermidis and E. faecalis were weaker than those of conventional oral cephalosporins but antibacterial activities against Gram-negative bacteria were almost the same as those of cehpem antibiotics of Fuji's group 5. 2. Peak serum concentrations of CFIX after oral doses of 3 and 6 mg/kg were, respectively, 1.51~4.89 μg/ml at 2~6 hours and 3.22~7.76 μg/ml at 4~8 hours. Serum concentrations of CFIX were dose-dependent in a patient given 3 and 6 mg/kg in a cross-over study. 3. CFIX granules were administered mainly to children suffering from respiratory tract infection, otitis media and urinary tract infection at a dose of 3 mg/kg b.i.d. or t.i.d. for 3~7 days. The clinical responses to CFIX were excellent to good in 44 of the 50 children with infections, with an effectiveness rate of 88{\%}. 4. Thirty-five strains of the 40 clinical isolates were eradicated by the treatment with CFIX. The bacteriological eradication rate was 87.5{\%}. 5. Side effects observed were diarrhea and soft stool in 2 patients each, and elevated GOT · GPT and eosinophilia in 1 patient each. These symptoms and laboratory abnormalities disappeared on the day after the completion of therapy with CFIX. From the above results it has been concluded that CFIX is a useful and safe antibiotic for treating various bacterial infections in children.",
author = "K. Sunakawa and N. Saito and Y. Ishizuka and S. Iwata and N. Kumagai and T. Yokota and T. Asaishi and S. Kusano and Y. Sato and Y. Kusumoto",
year = "1986",
language = "English",
volume = "39",
pages = "1035--1054",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "4",

}

TY - JOUR

T1 - Fundamental and clinical studies of cefixime granules in pediatrics

AU - Sunakawa, K.

AU - Saito, N.

AU - Ishizuka, Y.

AU - Iwata, S.

AU - Kumagai, N.

AU - Yokota, T.

AU - Asaishi, T.

AU - Kusano, S.

AU - Sato, Y.

AU - Kusumoto, Y.

PY - 1986

Y1 - 1986

N2 - Fundamental and clinical studies of cefixime (CFIX) granules, a new oral cephalosporin, were carried out with the following results: 1. The MICs of CFIX against 234 clinical isolates were determined. Antibacterial activities of the drug against S. aureus, S. epidermidis and E. faecalis were weaker than those of conventional oral cephalosporins but antibacterial activities against Gram-negative bacteria were almost the same as those of cehpem antibiotics of Fuji's group 5. 2. Peak serum concentrations of CFIX after oral doses of 3 and 6 mg/kg were, respectively, 1.51~4.89 μg/ml at 2~6 hours and 3.22~7.76 μg/ml at 4~8 hours. Serum concentrations of CFIX were dose-dependent in a patient given 3 and 6 mg/kg in a cross-over study. 3. CFIX granules were administered mainly to children suffering from respiratory tract infection, otitis media and urinary tract infection at a dose of 3 mg/kg b.i.d. or t.i.d. for 3~7 days. The clinical responses to CFIX were excellent to good in 44 of the 50 children with infections, with an effectiveness rate of 88%. 4. Thirty-five strains of the 40 clinical isolates were eradicated by the treatment with CFIX. The bacteriological eradication rate was 87.5%. 5. Side effects observed were diarrhea and soft stool in 2 patients each, and elevated GOT · GPT and eosinophilia in 1 patient each. These symptoms and laboratory abnormalities disappeared on the day after the completion of therapy with CFIX. From the above results it has been concluded that CFIX is a useful and safe antibiotic for treating various bacterial infections in children.

AB - Fundamental and clinical studies of cefixime (CFIX) granules, a new oral cephalosporin, were carried out with the following results: 1. The MICs of CFIX against 234 clinical isolates were determined. Antibacterial activities of the drug against S. aureus, S. epidermidis and E. faecalis were weaker than those of conventional oral cephalosporins but antibacterial activities against Gram-negative bacteria were almost the same as those of cehpem antibiotics of Fuji's group 5. 2. Peak serum concentrations of CFIX after oral doses of 3 and 6 mg/kg were, respectively, 1.51~4.89 μg/ml at 2~6 hours and 3.22~7.76 μg/ml at 4~8 hours. Serum concentrations of CFIX were dose-dependent in a patient given 3 and 6 mg/kg in a cross-over study. 3. CFIX granules were administered mainly to children suffering from respiratory tract infection, otitis media and urinary tract infection at a dose of 3 mg/kg b.i.d. or t.i.d. for 3~7 days. The clinical responses to CFIX were excellent to good in 44 of the 50 children with infections, with an effectiveness rate of 88%. 4. Thirty-five strains of the 40 clinical isolates were eradicated by the treatment with CFIX. The bacteriological eradication rate was 87.5%. 5. Side effects observed were diarrhea and soft stool in 2 patients each, and elevated GOT · GPT and eosinophilia in 1 patient each. These symptoms and laboratory abnormalities disappeared on the day after the completion of therapy with CFIX. From the above results it has been concluded that CFIX is a useful and safe antibiotic for treating various bacterial infections in children.

UR - http://www.scopus.com/inward/record.url?scp=0022516875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022516875&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 1035

EP - 1054

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 4

ER -